Cannabis Bioscience International Holdings, Inc. (CBIH) EBITDA Margin (2022 - 2026)
Cannabis Bioscience International Holdings (CBIH) posted EBITDA Margin of 832.3% for Q1 2026, down 362.4% sequentially from 180.0% in Q4 2025, and up 3324.0% YoY from 24.31% in Q1 2025.
Cannabis Bioscience International Holdings, Inc. (CBIH) EBITDA Margin (2022 - 2026) Analysis & Trends
Cannabis Bioscience International Holdings has reported EBITDA Margin for 5 years, with the latest figure at 832.3% in Q1 2026.
- Quarterly EBITDA Margin rose 3324.0% year-over-year to 832.3% in Q1 2026, while the trailing twelve-month figure through Feb 2026 was 322.6% (down 23069.0% YoY) and the FY2025 annual result came in at 139.05%, up 5631.0% from the prior year.
- EBITDA Margin eased to 832.3% in Q1 2026 per CBIH's latest filing, from 180.0% in the prior quarter.
- Over five years, EBITDA Margin peaked at 39.06% in Q2 2024 and troughed at 865.54% in Q1 2025.
- A 5-year average of 353.4% and a median of 275.89% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin soared 55324 bps in 2024, then plunged 42619 bps in 2025.
- Over 5 years, EBITDA Margin stood at 222.34% in 2022, then jumped by 33 bps to 148.26% in 2023, then soared by 46 bps to 80.31% in 2024, then tumbled by 124 bps to 180.0% in 2025, then sank by 362 bps to 832.3% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 832.3%, 180.0%, and 309.02% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -832.30% |
| Nov 30, 2025 | -180.00% |
| Aug 31, 2025 | -309.02% |
| May 31, 2025 | -385.91% |
| Feb 28, 2025 | -865.54% |
| Nov 30, 2024 | -80.31% |
| Aug 31, 2024 | -54.56% |
| May 31, 2024 | -39.06% |
| Feb 29, 2024 | -439.35% |
| Nov 30, 2023 | -148.26% |
| Aug 31, 2023 | -242.77% |
| May 31, 2023 | -592.30% |
| Feb 28, 2023 | -555.81% |
| Nov 30, 2022 | -222.34% |